Switching from Viibryd 30 mg to Qelbree
You cannot directly switch from Viibryd (vilazodone) 30 mg to Qelbree (viloxazine) because these medications treat completely different conditions and have incompatible mechanisms of action. Viibryd is an antidepressant for major depressive disorder, while Qelbree is a non-stimulant medication for ADHD 1, 2.
Critical Clarification Needed
This question appears to reflect a fundamental misunderstanding about these medications:
- Viibryd (vilazodone): A selective serotonin reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist approved for major depressive disorder 1
- Qelbree (viloxazine): A noradrenergic medication approved for attention-deficit/hyperactivity disorder (ADHD) 2
These are not interchangeable medications. The similar-sounding names may cause confusion, but they have entirely different therapeutic indications.
If You Need to Discontinue Viibryd
If the goal is to stop Viibryd (regardless of starting Qelbree), follow these steps:
Tapering Strategy
Gradual dose reduction over days to weeks is essential to minimize discontinuation syndrome 1, 3, 4. Abrupt discontinuation can cause:
- Nausea and mood changes
- Irritability and agitation
- Dizziness and electric shock sensations (paresthesia)
- Anxiety, confusion, sweating
- Headache, sleep problems
- Hypomania, tinnitus, seizures 1
Recommended Taper Approach
For Viibryd 30 mg (noting that standard dosing is 20 mg or 40 mg 1):
- Reduce to 20 mg daily for 1-2 weeks
- Then reduce to 10 mg daily for 1-2 weeks
- Then discontinue
Monitor closely for withdrawal symptoms and depressive relapse throughout the taper 3, 4. The taper duration should be extended if withdrawal symptoms emerge.
If Starting Qelbree for ADHD
If the patient has comorbid ADHD requiring Qelbree treatment:
Washout Period
Allow at least 7-14 days after complete Viibryd discontinuation before starting Qelbree 3, 4. This washout period:
- Minimizes drug interaction risks
- Allows assessment of baseline symptoms
- Reduces confusion about which medication causes any adverse effects
Qelbree Initiation
Start Qelbree according to standard dosing 2:
- Adults: Begin 200 mg once daily, may increase weekly by 200 mg to maximum 600 mg daily
- Take with or without food
- Monitor blood pressure and heart rate before starting and periodically during treatment
Critical Safety Considerations
Suicidal Ideation Risk
Both medications carry warnings about suicidal thoughts and behaviors 1, 2:
- Viibryd: Black box warning for increased suicidal thinking in young adults with depression
- Qelbree: Higher rates of suicidal ideation in ADHD patients (0.9% pediatric, 1.6% adult vs. placebo)
Close monitoring is mandatory during any medication transition, especially in the first few months 2.
Drug Interactions
- Qelbree is contraindicated with MAOIs and sensitive CYP1A2 substrates 2
- Viibryd requires caution with serotonergic drugs to avoid serotonin syndrome 1
Common Pitfall
The most common error would be attempting to "switch" these medications as if they were equivalent antidepressants. They are not. If both depression and ADHD require treatment, this requires careful sequential management with appropriate washout periods, not a simple medication switch 3, 4.
Reassess the clinical indication: Is the patient being treated for depression, ADHD, or both? The answer determines whether discontinuing Viibryd and starting Qelbree is even clinically appropriate.